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Immunosuppressive drug therapy is required to treat patients with autoimmune disease 
and patients who have undergone organ transplantation. The main targets of the immu-
nosuppressive drugs tacrolimus and mycophenolic acid (MPA; the active metabolite of 
mycophenolate mofetil) are T cells. It is currently unknown whether these immunosup-
pressive drugs have an effect on DNA methylation—an epigenetic regulator of cellular 
function. Here, we determined the effect of tacrolimus and MPA on DNA methylation 
of the gene promoter region of interferon gamma (IFNγ), a pro-inflammatory cytokine. 
Total T  cells, naive T  cells (CCR7+CD45RO−), and memory T  cells (CD45RO+ and 
CCR7−CD45RO−) were isolated from CMV seropositive healthy controls and stimulated 
with α-CD3/CD28 in the presence or absence of tacrolimus or MPA. DNA methylation 
of the IFNγ promoter region was quantified by pyrosequencing at 4 h, days 1, 3, and 
4 after stimulation. In parallel, T-cell differentiation, and IFNγ protein production were 
analyzed by flow cytometry at days 1 and 3 after stimulation. Our results show that 
MPA induced changes in IFNγ DNA methylation of naive T cells; MPA counteracted the 
decrease in methylation after stimulation. Tacrolimus did not affect IFNγ DNA methyl-
ation of naive T cells. In the memory T cells, both immunosuppressive drugs did not 
affect IFNγ DNA methylation. Differentiation of naive T cells into a central-memory-like 
phenotype (CD45RO+) was inhibited by both immunosuppressive drugs, while differenti-
ation of memory T cells remained unaffected by both MPA and tacrolimus. IFNγ protein 
production was suppressed by tacrolimus. Our results demonstrate that MPA influenced 
IFNγ DNA methylation of naive T cells after stimulation of T cells, while tacrolimus had no 
effect. Both tacrolimus and MPA did not affect IFNγ DNA methylation of memory T cells.
Keywords: interferon-gamma, epigenetics, polyclonal activation, remethylation, transplantation immunology, 
in vitro
inTrODUcTiOn
Patients who have undergone organ transplantation as well as patients with autoimmune disease 
require lifelong immunosuppression to inhibit the immune response toward alloantigen or autoanti-
gen. This immune response involves interaction between different immune cells including dendritic 
cells, macrophages, T, and B cells. T cells proliferate, differentiate, and produce effector cytokines 
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in response to antigen (1, 2) and therefore immunosuppressive 
drugs are often designed to suppress T-cell activity.
After activation, the differentiation of T cells is regulated to 
great extent by DNA methylation—an essential epigenetic regula-
tor of several cellular functions (3–5). DNA methylation is the 
addition of a methyl group on a cytosine (C) that is followed by a 
guanine (G) in the DNA, also known as a CpG dinucleotide. High 
methylation in the promoter region of a gene is related to a closed 
chromatin structure and transcriptional silencing of the gene 
(6, 7). When T cells differentiate during an immune response, the 
promoter regions of various effector genes become demethylated, 
thereby allowing the cells to upregulate these genes and produce 
effector cytokines (8, 9). Naive T cells are therefore characterized 
by methylated promoter regions of effector genes, whereas effec-
tor and memory T cells are demethylated at those regions.
Epigenetic regulators such as DNA methylation are dynamic 
and susceptible to cues from the environment (10, 11). These 
cues include internal factors such as cytokines and hormones as 
well as external factors such as food, toxins, and drugs. Several 
common-used pharmaceutical drugs, not designed as epigenetic 
drugs, have an effect on epigenetic mechanisms in the cell (12, 13). 
These findings suggest that immunosuppressive drugs could 
affect DNA methylation in T cells and thereby modulate T-cell 
function.
Today, the immunosuppressive drugs that are most often 
prescribed to organ transplant recipients include tacrolimus 
and mycophenolate mofetil (14, 15). Tacrolimus represses 
the calcineurin pathway downstream of the T-cell receptor. 
It inhibits calcineurin phosphatase activity, thereby reducing 
levels of dephosphorylated nuclear factor of activated T (NFAT) 
lymphocytes, which ultimately inhibits T-cell activation (16, 17). 
Mycophenolate mofetil’s active ingredient is mycophenolic acid 
(MPA). MPA is an inhibitor of inosine monophosphate dehydro-
genase (IMPDH), a key enzyme in de novo purine synthesis (18). 
Inhibition of IMPDH reduces synthesis of guanosine nucleotides, 
which are essential for DNA synthesis in T  cells, resulting in 
reduced proliferation of T cells (19, 20). Despite the fact that the 
mechanism of action is largely known for these two drugs, it is not 
known whether their effect on cellular function involves epige-
netic regulation, or whether they affect the epigenetic regulation 
of cytokine expression. A further understanding of the effect of 
different immunosuppressive drugs on epigenetic regulators of 
T-cell function will contribute to optimization of the immuno-
suppressive regimen.
We hypothesized that tacrolimus and MPA induce changes 
in DNA methylation of T  cells. We focus on promoter DNA 
methylation of the pro-inflammatory cytokine interferon gamma 
(IFNγ) which plays a prominent role in immune responses. Not 
only have high expression levels of IFNγ been linked to acute 
rejection after organ transplantation (21–23), it is also highly 
expressed during the inflammation seen in autoimmunity (24, 25). 
 IFNγ expression—along with that of many other cytokines—is 
known to be regulated by DNA methylation (26–28). To study the 
effect of immunosuppressive drugs on IFNγ DNA methylation 
after activation of T  cells, we stimulated T  cells in  vitro in the 
absence or presence of tacrolimus or MPA. After stimulation, 
DNA methylation was measured at two sites within the IFNγ 
promoter. Since DNA methylation is cell-type specific (29), the 
experiments were performed on total T cells as well as on isolated 
naive and memory T cells.
MaTerials anD MeThODs
study subjects
Our study population consisted of 19 healthy individuals aged 
between 26 and 75 (68% female). Peripheral blood of these 
subjects was collected after informed consent and according to 
biobank protocol with approval of the local ethics committee 
(MEC-2010-022). We chose to study healthy individuals to elimi-
nate confounding effects of disease on DNA methylation (30). It 
is also known that IFNγ DNA methylation is significantly lower 
in CMV seropositive individuals than in CMV seronegative indi-
viduals (31). To compose a homogeneous group and eliminate 
CMV effects on inter-individual differences in methylation levels, 
only CMV seropositive individuals were included in the study.
isolation of Total T cells, naive T cells, 
and Memory T cells
Peripheral blood mononuclear cells (PBMCs) were isolated from 
the peripheral blood by density gradient centrifugation using 
Ficoll-Paque (GE Healthcare, Chicago, IL, USA). Isolated PBMCs 
were stored at −140°C until further use. Total T cells were isolated 
from the PBMCs by magnetic cell separation on the autoMACS 
(Miltenyi Biotech, Bergisch Gladbach, Germany) according to 
the pan T cell protocol using the deplete S settings. Purities were 
>90% CD3+ cells after isolation.
The naive and memory T-cell populations were isolated from 
the PBMCs using fluorescence-activated cell sorting (FACS) by 
the BD FACSAria™ II (BD Biosciences, San Jose, CA, USA). The 
PBMCs were stained with CD3 Brilliant Violet 510 (Biolegend, 
San Diego, CA, USA), CD4 Pacific Blue (BD Biosciences), CD8 
APC-cy7 (BD Biosciences), CD45RO APC (Biolegend), CCR7 
PE-cy7 (BD Biosciences), and to exclude non-viable cells the 
cells were also stained with 7AAD PerCP (BD Biosciences). Naive 
cells were defined as CCR7+CD45RO−, central memory cells as 
CCR7+CD45RO+, effector memory (EM) as CCR7−CD45RO+, 
and the highly differentiated EMRA cells as CCR7−CD45RO− 
(32). After cell sorting, the purities were >95% for each sorted 
fraction.
T-cell stimulation
The T cells were stimulated for 4 days with α-CD3/CD28 coated 
Dynabeads® (Gibco, Waltham, MA, USA) in a bead to cell ratio of 
1:1 at day 0. Fifty thousand cells were cultured per well in a 96-well 
plate. The cells were cultured in the absence or presence of tac-
rolimus, MPA or 5-aza-2′deoxycytidine (decitabine). Tacrolimus 
(Prograf®, Astellas Pharma, Tokyo, Japan) was added to the cells 
in a concentration of 10  ng/mL which is a clinically relevant 
concentration that is reached in transplant recipients (33). MPA 
(Sigma-Aldrich, St. Louis, MO, USA) was added to the cells in a 
concentration of 0.2 µg/mL, a concentration at which the cells are 
still able to proliferate. Our positive control, the demethylating 
agent decitabine (Sigma-Aldrich) (34), was added to the cells in 
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a concentration of 10−6 M, a concentration at which the cells are 
still able to proliferate. Each drug-treated sample has a matched 
negative control (stimulation alone).
The cells were incubated at 37°C in 5% CO2 and harvested 
at 4  h, days 1, 3, and 4 for DNA methylation analysis, and at 
days 1 and 3 for flow cytometry analysis. To assess viability and 
proliferation, the cells were counted before and after stimulation 
using conventional light microscopy and Trypan Blue staining 
(Thermo Fisher Scientific, Waltham, MA, USA).
Flow cytometry
Flow cytometry was used to determine the phenotype of T cells 
immediately after isolation and at days 1 and 3 after stimulation. 
We also measured the percentage of IFNγ producing cells at 
these time points. The samples were treated with Brefeldin A 
(GolgiPlug™, BD Biosciences) for 16 h prior to flow cytometry 
analysis. The monoclonal antibodies used for cell surface staining 
were the same as previously described for the FACS cell sorting. 
In addition, the cells were permeabilized using permeabilize 
solution 2 (BD Biosciences), and stained for intracellular IFNγ 
with FITC labeled IFNγ (BD Biosciences). The cells were then 
analyzed on the FACSCanto II (BD Biosciences) with FACSDiva 
software. All flow cytometry data were analyzed using Kaluza 
software 1.3 (Beckman Coulter, Brea, CA, USA).
Dna isolation, Bisulfite conversion,  
and Pcr
After harvesting, the cells they were pelleted, frozen in liquid 
nitrogen, and stored at −80°C until bisulfite conversion. The T-cell 
pellets were digested with proteinase K and bisulfite treatment 
was performed using the EZ DNA Methylation-Direct kit (Zymo 
Research, Irvine, CA, USA) according to the manufacturer’s 
protocol. Bisulfite treatment introduces methylation-dependent 
changes in the DNA, demethylated cytosines are converted into 
uracil whereas methylated cytosines remain unchanged. The 
bisulfite-treated DNA was amplified by PCR. A 230 base pair 
region of the IFNγ promoter was amplified using the Pyromark 
PCR kit (Qiagen, Venlo, The Netherlands). A forward primer 
with the sequence 5′-ATGGTATAGGTGGGTATAATGG-3′ 
and a biotin-labeled reverse primer with the sequence 
5′-CAATATACTACACCTCCTCTAACTAC-3′ (Sigma-Aldrich) 
were used, both at a concentration of 10 pmol/μL (31). The PCR 
conditions were 15  min at 95°C, 45 cycles of 30  s 94°C, 30  s 
58°C, 30  s 72°C followed by 10  min at 72°C, and final storage 
at room temperature (21°C). Prior to pyrosequencing, the PCR 
product was visualized on a 1% agarose gel to verify the size of 
the amplicon. Two important CpG sites are inside this amplicon, 
CpG -186 and CpG -54. These sites are within binding domains 
of transcription factors (26, 31).
Pyrosequencing
Pyrosequencing is an excellent technique to quantitatively 
measure DNA methylation at single CpG-site resolution, yield-
ing accurate, and reproducible results (35, 36). The IFNγ PCR 
product was sequenced using a PyroMark Q24 pyrosequencer 
(Qiagen). Minor adjustments were made to the manufacturer’s 
protocol: to immobilize the PCR product 1  µL Streptadivin 
Sepharose High Performance Beads (GE Healthcare) was used 
per  sequence reaction and annealing of the sequence primers 
was done for 3  min at 80°C. The CpG -186 sequence primer 
was 5′-GGTGGGTATAATGGG-3′ and the CpG -54 sequence 
primer was 5′-ATTATTTTATTTTAAAAAATTTGTG-3′, both 
at a concentration of 10 µM (31). Two DNA methylation stand-
ards were used as control, human high, and low methylated DNA 
(EpigenDx, Hopkinton, MA, USA). Research shows that methyla-
tion at adjacent sites is correlated (37) therefore the methylation 
percentages of the two CpG sites, site -54 and -186, were pooled 
per individual and the mean DNA methylation percentage is 
presented in the results.
statistical analysis
Statistical analyses were performed with SPSS Statistics version 
21.0 (IBM Corp., Armonk, NY, USA). The Mann–Whitney U test 
was used for unpaired analysis to identify differences between 
the conditions at a certain time point. The Wilcoxon signed-rank 
test was used for paired analysis when comparing different time 
points within a condition. A p-value <0.05 was considered statis-
tically significant.
resUlTs
effect of Tacrolimus and MPa on IFNγ 
Dna Methylation of Total T cells
To exclude complete cell cycle arrest as a cause for methylation 
differences, we compared cell numbers under the different con-
ditions after stimulation. Cell numbers were lower if cells were 
cultured with either tacrolimus, MPA, or decitabine than if the 
cells were cultured without those factors, but due to overlapping 
ranges this difference was not statistically significant (Figure S1 in 
Supplementary Material). Our results suggest that the cells were 
still able to proliferate under the chosen concentrations of the 
different drugs.
To determine the changes in DNA methylation after T-cell 
stimulation, we analyzed IFNγ promoter methylation at several 
time points after stimulation. IFNγ DNA methylation of total 
T  cells increased significantly after stimulation with α-CD3/
CD28 (p = 0.002; Figure 1B). Stimulated T cells showed a median 
DNA methylation percentage of 47% (range: 35–59%) at day 0 
and this was significantly increased at day 4 (59%; 46–66%).
DNA methylation of T cells cultured in the presence of tacroli-
mus increased significantly from 49 (42–59%) to 53% (44–67%) 
(p = 0.043) and did not differ significantly from the stimulated 
condition at any of the given time points (Figure  1B). DNA 
methylation of T cells cultured in the presence of MPA increased 
from 48 (43–56%) to 61% (46–66%) and also did not differ 
significantly from the stimulated condition (Figure  1B). Our 
positive control, T  cells cultured in the presence of decitabine, 
significantly decreased in DNA methylation between day 0 and 
day 4 (p = 0.028; Figure 1B).
Since our total T-cell population was a heterogeneous mix-
ture of naive and memory T  cells with different methylation 
profiles (29), we continued to study isolated cell populations to 
infer whether tacrolimus or MPA did influence these cell types 
individually.
FigUre 1 | (a) A representative example of the CD3+ purity and viability after MACS isolation. (B) Median and interquartile range of IFNγ DNA methylation at days 
0, 1, 3, and 4 after α-CD3/CD28 stimulation of total T cells under the different culture conditions: stimulated (n = 15), decitabine (n = 7), tacrolimus (n = 5), 
mycophenolic acid (n = 4). p-Values were calculated with a Wilcoxon matched pairs test.
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effect of Tacrolimus and MPa on iFnγ 
Dna Methylation of naive and Memory  
T cells
Pure naive (CCR7+CD45RO−) (Figure  2A) and memory 
(CD45RO+ and CCR7−CD45RO−) (Figure  2C) T-cell subsets 
were stimulated separately. IFNγ DNA methylation signifi-
cantly decreased in the naive start population in the absence of 
tacrolimus or MPA, from 78 (75–83%) at day 0 to 67% (61–77%) 
at day 4 (p = 0.011; Figure 2B). The two immunosuppressive 
drugs had differential effects on this reduction in DNA meth-
ylation. While tacrolimus had no effect, MPA neutralized the 
effect of stimulation significantly and DNA methylation did not 
decrease (78%; 76–82% at day 0 and 77%; 75–78% at day 4). This 
differential effect resulted in a significant difference between 
stimulation only and the addition of MPA on day 3 (p = 0.005) 
and day 4 (p = 0.014; Figure 2B).
In the total memory start population, IFNγ DNA methylation 
significantly increased in the absence of tacrolimus or MPA, 
from 24 (19–31%) at day 0 to 38% (30–46%) at day 4 (p = 0.012; 
Figure  2D). This increase was not affected by tacrolimus nor 
MPA, both these conditions were not significantly different from 
stimulation alone.
As explained in the Section “Introduction,” we expected 
effector-gene promoters to demethylate after activation to allow 
transcription of the corresponding effector gene. We observed 
this in the naive T cells, demethylation of the IFNγ promoter 
took place after 3  days of stimulation (Figure  2B). However, 
the IFNγ promoter of the memory T cells did not demethylate 
after 1, 3, or 4 days after stimulation (Figure 2D). Therefore, we 
speculated that demethylation occurred in a shorter timeframe 
than 24 h, to allow memory T cells to produce IFNγ protein. 
To address this question, we harvested memory T cells at 4 h 
after stimulation and indeed we observed a significant decrease 
(3–12%; p = 0.043) in methylation followed by remethylation 
to base levels after 24 h (Figure 3).
Phenotypic changes after α-cD3/cD28 
stimulation of the naive T cells
The isolated naive T cells, which were CCR7+CD45RO− at day 
0, were analyzed for the expression of CD45RO and CCR7 
after 1 and 3 days of stimulation in the absence and presence 
of tacrolimus or MPA. CD4+ and CD8+ T cells were gated sepa-
rately (Figure 4), the percentages CD4+/CD8+ do not differ sig-
nificantly between the conditions (Figure S2 in Supplementary 
Material). After 1  day of stimulation, the phenotype did not 
differ significantly from day 0 in both CD4+ and CD8+ T cells. 
On day 3, there was a significant shift toward CD45RO+ cells 
in the stimulated condition (p = 0.008). The shift was observed 
in all three conditions and in both the CD4+ and CD8+ T cells 
(Figures  4B,C). These cells, which were CD45RO− at day 0, 
upregulated their CD45RO expression showing a central-mem-
ory-like phenotype at day 3. When we compared the different 
conditions with stimulation only at day 3, tacrolimus (p = 0.013) 
and MPA (p = 0.039) significantly repressed CD4+ differentia-
tion and MPA also significantly repressed CD8+ differentiation 
(p = 0.014; Figures 4B,C).
Phenotypic changes after α-cD3/cD28 
stimulation of the Memory T cells
The isolated memory T  cells, which were CD45RO+ and 
CCR7−CD45RO− at day 0, were also analyzed by flow 
cytometry after 1 and 3 days of stimulation in the absence or 
presence of tacrolimus or MPA. CD4+ and CD8+ T cells were 
gated separately (Figure 5). The percentage of CD8+CD45RO+ 
cells increased significantly after 3  days of stimulation, both 
in the CCR7+ (p = 0.008) and CCR7− (p = 0.021) population 
(Figure 5C). In the CD4+ population, we observed an increase 
in the CCR7+CD45RO+ population (p = 0.011) and a decrease 
in the CCR7− population (p =  0.021) (Figure  5B). When we 
compared the different conditions with stimulation only at day 
3, no significant differences were found.
FigUre 2 | (a) A representative example of the naive CCR7+CD45RO− T cells after sorting. (B) Median and interquartile range of IFNγ DNA methylation of sorted 
naive T cells stimulated in the absence (n = 9) or presence of tacrolimus (n = 3) or mycophenolic acid (MPA) (n = 4). (c) A representative example of the memory 
CD45RO+ and CCR7−CD45RO− T cells after sorting. (D) Median and interquartile range of IFNγ DNA methylation of the sorted memory T cells stimulated in the 
absence (n = 9) or presence of tacrolimus (n = 3) or MPA (n = 3). The pink dots in the fluorescence-activated cell sorting plots (a,c) represent the CD4+ cells and 
the blue dots the CD8+ cells. p-Values were calculated with a Wilcoxon matched pairs test (T = 0 vs T = 3 within one condition) or Mann–Whitney U test (between 
conditions).
FigUre 3 | Median and interquartile range of IFNγ DNA methylation of the 
sorted memory T cells at 0, 4, and 24 h after α-CD3/CD28 stimulation 
(n = 5). p-value was calculated with a Wilcoxon matched pairs test.
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iFnγ Protein Production of the Memory 
Population
Interferon gamma protein production was measured using intra-
cellular staining in both the sorted naive T cells and the sorted 
memory T cells (Figure 6). The sorted naive T cells did not produce 
IFNγ protein at day 1 after stimulation (data not shown) while 
10% (3–19%) of the sorted memory T cells did produce IFNγ. 
Tacrolimus significantly inhibited IFNγ production, hardly any 
cells produced IFNγ in the presence of tacrolimus (Figure 6B). 
MPA did not have a significant effect on IFNγ production and the 
percentage IFNγ producing cells did not differ from stimulation 
only. Three days after stimulation of the sorted memory T cells, 
few cells still produce IFNγ both in the presence and absence of 
tacrolimus or MPA.
DiscUssiOn
To our knowledge, this is the first study to investigate the effect 
of immunosuppressive medication on DNA methylation of 
primary T cells (38, 39). The study design allowed us to track 
changes over time after activation. Also, by combining the 
results of our analyses of DNA methylation, phenotype, and 
protein production, we were able to determine the effects of 
FigUre 4 | Phenotypic changes of the naive T cells in the absence or presence of tacrolimus or mycophenolic acid (MPA): stimulated (n = 9), tacrolimus (n = 3), 
and MPA (n = 4). (a) A representative gating example of the CD4+ T cells directly after isolation (T = 0) and at day 1 (T = 1) and day 3 (T = 3) after stimulation. 
(B) Median percentages of CD4+ subsets in the absence or presence of tacrolimus or MPA at days 0, 1, and 3. (c) Median percentages of CD8+ subsets in the 
absence or presence of tacrolimus or MPA at days 0, 1, and 3. *p < 0.05 (Mann–Whitney U test to compare two conditions); #p < 0.05 (Wilcoxon matched pairs 
test to compare T = 0 with T = 3 within one condition).
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immunosuppressive drugs on cellular dynamics after T-cell 
activation. Our results show that after T-cell activation, MPA 
affected IFNγ DNA methylation of naive T cells but not that of 
memory T cells, while tacrolimus had no effect on IFNγ DNA 
methylation of T cells (Figures 1 and 2).
The mechanism by which MPA counteracts the effect of 
T-cell stimulation on IFNγ DNA methylation is unknown. We 
can however suggest a possible mechanism by looking at the 
different enzymes that regulate DNA methylation in general. 
DNA methyl transferases (DNMTs) are a family of enzymes that 
maintain DNA methylation during cell division (DNMT1) and 
cause de novo DNA methylation (DNMT3a,b) (4). Lower activ-
ity of DNMT1 leads to passive demethylation, the methylation 
“dilutes” during cell division (5, 40). Possibly, MPA has a direct or 
FigUre 5 | Phenotypic changes of the memory T cells in the absence or presence of tacrolimus or mycophenolic acid (MPA): stimulated (n = 9), tacrolimus (n = 3), 
and MPA (n = 3). (a) A representative gating example of the CD8+ subsets of the stimulated cells directly after isolation (T = 0) at day 1 (T = 1) and day 3 (T = 3) 
after stimulation. (B) Median percentages of CD4+ subsets in the absence or presence of tacrolimus or MPA at days 0, 1, and 3. (c) Median percentages of CD8+ in 
the absence or presence of tacrolimus or MPA at days 0, 1, and 3. #p < 0.05 (Wilcoxon matched pairs test to compare T = 0 with T = 3 within one condition).
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indirect effect on DNMT1 activity during differentiation of naive 
T cells. A similar suggestion was made by He et al. (41) in relation 
to an increased CD70 expression induced by MPA.
While the two drugs’ effects on DNA methylation were 
different, their effects on T-cell differentiation were similar 
(Figures 4 and 5). Tacrolimus and MPA both suppressed the dif-
ferentiation of naive T cells (CD45RO−) toward CD45RO+ cells. 
This phenotypic marker is a characteristic marker for memory 
T cells (32) but it has been described as an activation marker 
as well (42, 43). Since tacrolimus inhibited differentiation of 
the naive T cells significantly but did not influence IFNγ DNA 
methylation of those cells, we believe that the differentiation 
can occur independently from changes in IFNγ DNA methyla-
tion. On the other hand, the changes in T-cell phenotype and 
IFNγ DNA methylation after stimulation alone both occur after 
3  days, indicating a relation between these two parameters. 
FigUre 6 | (a) A representative gating example of interferon gamma (IFNγ) production by the sorted memory T-cell population on day 1 after stimulation. 
(B) Percentages and median of IFNγ producing memory T cells on days 1 and 3 of all three conditions measured by intracellular staining and flow cytometry. 
p-Values were obtained with the Mann–Whitney U test.
8
Peters et al. The Effect of Immunosuppression on Interferon-Gamma DNA Methylation
Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 822
Taken together, the exact relationship between phenotypic 
changes and changes in IFNγ DNA methylation after stimula-
tion remains unclear.
While we had expected T  cells to become demethylated 
on their IFNγ promoter upon stimulation, we were surprised 
to note that, in both total T  cells and memory T  cells, IFNγ 
promoter methylation actually increased (Figures  1B and 
2D). In line with the results of previous studies (44, 45), IFNγ 
DNA methylation decreased shortly after stimulation of the 
memory T cells (Figure 3). After the demethylation phase of 
these cells, IFNγ DNA methylation returned to base-level and 
from day 1 onward DNA methylation steadily increased. Since 
the phenotype of the cells changed after stimulation, each time 
point reflected a heterogeneous cell population. This makes it 
difficult to assign the increasing IFNγ DNA methylation to a 
specific cell type. The ideal situation would be to isolate pure 
cell populations at each time point using surface markers 
before analyzing their methylation profile—this is practically 
challenging however.
We are currently uncertain what the biological reason is 
behind the increase in IFNγ DNA methylation (remethylation) 
that we observed. Similar remethylation of gene promoters after 
stimulation has thus far been reported for PD1 and IL2. Youngblood 
et al. (46) studied the PD1 locus in antigen-specific CD8+ T cells in 
mice and found that after 8 days of LCMV infection, the PD1 locus 
in effector cells had been partially remethylated. This finding was 
only seen in an acute infection model however: when the mice 
were chronically infected, the locus remained demethylated and 
the CD8+ cells became exhausted (46). A study on IL2 promoter 
DNA methylation in HIV-infected patients showed that IL2 DNA 
methylation was higher in all CD4+ EM subsets of HIV-infected 
patients than in those of healthy controls, indicating that chronic 
HIV infection increased methylation levels in these cell types 
(47). The remethylation of the IFNγ promoter that we observed 
may be similar to that of the PD1 and IL2 promoters described in 
the above-mentioned papers.
Although DNA methylation of IFNy was not affected by the 
presence of tacrolimus, IFNγ protein production by the memory 
cells was suppressed in the presence of tacrolimus (Figure  6). 
As mentioned in the Section “Introduction,” the mechanism of 
action of tacrolimus is known. Tacrolimus-induced inhibition 
of the calcineurin pathway inhibits the activity of NFAT, a tran-
scription factor that regulates IFNγ gene expression (48, 49). Our 
results demonstrate that this tacrolimus-induced suppression 
of IFNγ protein production is independent of changes in DNA 
methylation of IFNγ.
Mycophenolic acid did not affect the percentage of IFNγ pro-
ducing memory cells in our experiments but the results reported 
in literature vary. He et  al. (41) reported that MPA inhibited 
IFNγ production in CD4+ T cells after α-CD3/CD28 stimulation. 
Whereas Egli et al. (50) did not find a strong decrease in IFNγ 
production after adding MPA to CMV-stimulated PBMCs. In 
both studies, IFNγ concentration was measured in the culture 
supernatant, and such concentration is strongly related to the 
number of cells present. Since proliferation decreases under 
the influence of MPA (18, 51), cytokine production should be 
corrected for cell numbers as we did by measuring intracel-
lular IFNγ. In addition, Egli et  al. (50) did not measure T-cell 
specific IFNγ production and since NK cells are also capable of 
producing IFNγ this may have influenced their results. These 
experimental differences could explain the difference between 
our findings and the results reported in literature.
Here, we focused on the IFNγ gene promoter to study differ-
ences in DNA methylation. Possibly, immunosuppressive drugs 
have much stronger effects on DNA methylation of other genes or 
even at intergenic regions (12). To find the most affected regions, 
a genome-wide methylation study could be performed. Due to 
the explorative nature of this study, a genome-wide approach was 
outside the scope of this paper.
The findings presented here demonstrate that IFNγ DNA 
methylation in T cells was not affected in the same manner by 
tacrolimus and MPA and therefore we conclude that these immu-
nosuppressive drugs differentially affect IFNγ DNA methylation 
in CMV seropositive individuals. Our study also shows that naive 
and memory T cells did not only have distinct DNA methylation 
profiles, but also that they were not affected equally by the immu-
nosuppressive drugs studied. These findings may be of significance 
for future research into the efficacy of immunosuppressive drugs. 
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Knowledge on the effect of immunosuppressive drugs on DNA 
methylation of T-cell effector genes and thereby T-cell function 
could optimize the treatment regimen. When developing and 
testing immunosuppressive drugs, we recommend to include 
DNA methylation studies thereby improving our understanding 
of their effect on the function of patients’ immune cells.
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